New Mesothelioma Study Results
Between August 2001 and July 2002, a total of 42 patients with malignant pleural mesothelioma (MPM) were enrolled in a Phase I study that involved extrapleural pneumonectomy (EPP) and intraoperative hyperthermic cisplatin (IOHC). IOHC is heated cisplatin that is delivered into the cavity created during surgery when the mesothelioma and associated organs are removed. Intravenous administration of the drug amifostine was also used to try to ameliorate the cisplatin-induced renal toxicity. During thoracotomy, 13 patients were found to have unresectable disease and 29 patients had their MPM resected to smaller than 1 centimeter. Of the latter group, there were 22 men and 7 women patients, with a median age of 57 years. Here are the results of the study: Overall…